Videos

Survivor Kiana Wooten shares her story on genetic testing, overcoming sepsis and why choosing to stay flat was her most empowering medical decision.

New EGFR-targeting combos may improve response rates and durability for patients with head and neck cancer.

Dr. Alexander Meves explains how the Merlin CP-GEP test uses molecular data to help melanoma patients safely avoid unnecessary lymph node surgeries.

Physician Dr. Sheri Prentiss advocates for baseline measurements and proactive surveillance to detect and treat breast cancer-related lymphedema early.

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Discover how modern immunotherapy awakens T cells to shrink melanoma tumors, tracked by PET scans and used after surgery to prevent relapse.

Dr. Sara Nunnery and Dr. Neil Iyengar discuss metabolic health, GLP-1s and prescribing exercise to improve outcomes for breast cancer survivors.

Dry mouth and neck tightness from oral tongue cancer treatment shape daily life, managed with hydration, stretches, therapies and a head and neck Flexitouch device.

Expanding local access to clinical trials improves options by reducing barriers and bringing research opportunities closer to patients with cancer, Dr. Natalie Berger said.

Dr. Gregory Tiesi discusses TAMP, a targeted therapy that delivers chemotherapy directly to pancreatic tumors with fewer side effects.

In this closing segment, Dr. Gregory Vidal discusses the importance of patient engagement and empowerment throughout the course of ER-positive, HER2-negative metastatic breast cancer.

In this segment, Dr. Gregory Vidal discusses the role of estrogen receptor antagonists in the treatment of ER-positive, HER2-negative metastatic breast cancer following progression on prior endocrine therapy.

In this segment, Dr. Gregory Vidal explains what it means when endocrine therapy stops working in ER-positive, HER2-negative metastatic breast cancer and why resistance can develop over time.

In this segment, Dr. Gregory Vidal discusses practical steps patients can take to manage side effects while undergoing treatment for ER-positive, HER2-negative metastatic breast cancer.

In this segment, Dr. Gregory Vidal discusses how initial treatment options are selected for patients with ER-positive, HER2-negative metastatic breast cancer and highlights the importance of individualized care.

In this segment, Dr. Gregory Vidal explains why CDK4/6 inhibitors are commonly added to endocrine therapy in the treatment of ER-positive, HER2-negative metastatic breast cancer.

In this segment, Dr. Gregory Vidal explains how hormone, or endocrine, therapies work to slow or stop cancer growth in ER-positive, HER2-negative metastatic breast cancer.

Nurse Bridget Hopkins shares how she navigates metastatic breast cancer through second opinions, "YOLO" trips and the power of advanced care planning.

Christine Fader shares how her husband’s past trauma shaped his cancer treatment experience and why awareness and patient empowerment matter.

Multiple myeloma survivor JP Kealy and wife Annamarie share how to avoid cancer burnout and why this journey is a marathon, not a sprint.

Author and multiple myeloma survivor Jonathan Gluck shares how an unexpected diagnosis reshaped his identity and approach to living with uncertainty.

Dr. Susan MacDonald, a urologist who has been diagnosed with stage 4 breast cancer, launches a new vlog series for CURE, “Demystifying the Darkness.”

Author and survivor Parul Somani shares how patients with breast cancer can find peace of mind when clinical certainty is missing.

In this segment, Ms. Haupert shares the key questions and concerns she had when discussing treatment options for advanced melanoma. The conversation highlights how patients often prioritize understanding treatment effectiveness, potential side effects, and how therapy may impact their daily lives. She reflects on the importance of logistical considerations, including time commitment, frequency of visits, and overall burden of treatment. Dr. Morrison facilitates the discussion to emphasize how these factors influence patient decision making and underscore the need for clear, patient-centered communication. The segment illustrates that beyond clinical outcomes, patients are also focused on how treatment fits into their routines and responsibilities. This exchange reinforces the value of shared decision making in advanced melanoma, where aligning treatment choices with patient preferences and expectations is essential to optimizing both clinical and quality-of-life outcomes.

In this segment, Ms. Popolo discusses key priorities during initial visits with patients newly diagnosed with advanced melanoma. The conversation focuses on the importance of patient education, including helping individuals understand their diagnosis, treatment options, and the overall care pathway. She emphasizes setting clear expectations early, particularly around treatment goals, potential outcomes, and what patients may experience during therapy. The discussion also highlights the need to address common concerns, including side effects and the emotional impact of diagnosis, while ensuring that information is delivered in a clear and supportive manner. Dr. Morrison guides the exchange to underscore the role of the advanced practice provider in bridging clinical information with patient understanding. This segment reinforces the importance of communication, shared decision making, and establishing a strong foundation of trust at the start of the advanced melanoma treatment journey.

In this segment, Ms. Haupert shares her personal experience navigating advanced melanoma, offering valuable insight into the patient journey from diagnosis through treatment. She describes how her care was initiated, including whether she began with intravenous immunotherapy or transitioned to a subcutaneous approach, and reflects on what that experience was like at different stages of her treatment. The discussion highlights the practical and emotional aspects of receiving care, including how the treatment setting, whether in a community clinic or academic center, may influence the overall experience. Dr. Morrison guides the conversation to emphasize how individual patient journeys can vary based on treatment pathways and care environments. This segment brings a real-world perspective to advanced melanoma management, helping to contextualize clinical decisions through the lens of patient experience and reinforcing the importance of personalized care.

In this segment, Dr. Gregory Vidal outlines what a typical first-line treatment plan looks like for patients with ER-positive, HER2-negative metastatic breast cancer.

In this opening segment, Dr. Morrison provides a foundational overview of advanced melanoma, including how metastatic disease is currently defined and how treatment outcomes have evolved over the past decade. He discusses the shift in management driven by the introduction of immune checkpoint inhibitors, which have significantly improved survival outcomes compared with historical expectations. The conversation highlights how advances in therapy have led to more durable responses and better disease control for many patients, while also noting that outcomes can vary based on individual clinical factors. Dr. Morrison emphasizes the importance of understanding the current treatment landscape as a framework for evaluating newer approaches in care. This segment sets the clinical context for the discussion, preparing the audience for a deeper exploration of treatment delivery methods and their implications for patient experience in advanced melanoma.

In this segment, Dr. Gregory Vidal explains how biomarker test results directly influence treatment decisions in ER-positive, HER2-negative metastatic breast cancer.

Coverage from NCCN 2026 highlights global care delivery, younger patient needs, survivorship strategies and safer immunotherapy management.